姑息性胸部放疗中食管回避调强放疗以减少吞咽困难
本研究为计划设计研究,纳入15例接受30Gy/10次姑息性胸部放疗的肺癌患者,比较食管回避调强放疗(ES-IMRT,食管最大点剂量限制24Gy)与平行对穿野(POP)计划。ES-IMRT使食管中位平均剂量从16Gy降至7Gy,基于LKB-NTCP模型的有症状食管炎理论概率从13%降至2%,肺炎从5%降至3%,而GTV和PTV的中位NTD mean相似。
要点
- ES-IMRT将食管最大点剂量限制在24Gy,中位食管平均剂量由16Gy降至7Gy。
- LKB模型显示有症状食管炎概率由13%降至2%,肺炎由5%降至3%。
- GTV和PTV的中位NTD mean在POP与ES-IMRT计划间相似,提示不牺牲局部控制。
核心结论
- ES-IMRT可能降低晚期肺癌姑息性胸部放疗的治疗相关毒性,且不损害局部控制。
研究设计与样本
- 计划设计研究,纳入2015年8月至2016年1月间接受30Gy/10次姑息性胸部放疗的15例肺癌患者。
主要发现
- ES-IMRT使食管中位平均剂量从16Gy降至7Gy,肺中位平均剂量从8Gy降至7Gy。
- 基于LKB-NTCP模型,有症状食管炎(≥2级)理论概率从13%降至2%,肺炎(≥2级)从5%降至3%。
- POP计划与ES-IMRT计划的GTV和PTV中位NTD mean相似。
关键数值与推荐
- ES-IMRT计划通过限制食管最大点剂量至24Gy进行优化。
- 既往随机对照研究显示,体能状态好的患者接受35Gy10或更高剂量有生存获益,但食管炎发生率增加。
临床怎么用
- 对晚期肺癌行姑息性胸部放疗时,可采用ES-IMRT限制食管最大点剂量至24Gy以减少食管炎风险。
局限性
- 本研究为计划设计研究,样本量15例,未报告临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palliative thoracic radiotherapy is an effective technique to alleviate symptoms of disease burden in advanced-stage lung cancer patients. Previous randomized controlled studies demonstrated a survival benefit in patients with good performance status at radiation doses of 35Gy10 or greater but with an increased incidence of esophagitis. The objective of this planning study was to assess the potential impact of esophageal-sparing IMRT (ES-IMRT) compared to the current standard of care using parallel-opposed pair beams (POP). METHODS: In this study, 15 patients with lung cancer treated to a dose of 30Gy in 10 fractions between August 2015 and January 2016 were identified. Radiation treatment plans were optimized using ES-IMRT by limiting the max esophagus point dose to 24Gy. Using published Lyman-Kutcher-Burman normal tissue complication probabilities (LKB-NTCP) models, both plans were evaluated for the likelihood of esophagitis (≥ grade 2) and pneumonitis (≥ grade 2). RESULTS: Using ES-IMRT, the median esophageal and lung mean doses reduced from 16 and 8Gy to 7 and 7Gy, respectively. Using the LKB models, the theoretical probability of symptomatic esophagitis and pneumonitis reduced from 13 to 2%, and from 5 to 3%, respectively. The median normalize total dose (NTD mean) accounting for fraction size for the GTV and PTV of the clinically approved POP plans compared to the ES-IMRT plans were similar. CONCLUSION: Advanced radiotherapy techniques such as ES-IMRT may have clinical utility in reducing treatment-related toxicity in advanced lung cancer patients. Our data suggests that the rate of esophagitis can be reduced without compromising local control.
引用
- Granton PV, Palma DA, Louie AV, et al. Intentional avoidance of the esophagus using intensity modulated radiation therapy to reduce dysphagia after palliative thoracic radiation. Radiat Oncol. 2017. PMID: 28122566. doi:10.1186/s13014-017-0771-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。